Mereo BioPharma Group (MREO) Competitors $1.71 -0.04 (-2.29%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.73 +0.02 (+1.17%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MREO vs. SION, STOK, SYRE, PRAX, CRMD, CRON, NUVB, VERV, VALN, and MLYSShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Sionna Therapeutics (SION), Stoke Therapeutics (STOK), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), CorMedix (CRMD), Cronos Group (CRON), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Valneva (VALN), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Its Competitors Sionna Therapeutics Stoke Therapeutics Spyre Therapeutics Praxis Precision Medicines CorMedix Cronos Group Nuvation Bio Verve Therapeutics Valneva Mineralys Therapeutics Sionna Therapeutics (NASDAQ:SION) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Do institutionals & insiders believe in SION or MREO? 62.8% of Mereo BioPharma Group shares are held by institutional investors. 3.9% of Sionna Therapeutics shares are held by insiders. Comparatively, 5.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend SION or MREO? Sionna Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 56.38%. Mereo BioPharma Group has a consensus target price of $7.40, indicating a potential upside of 332.75%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is SION or MREO more profitable? Sionna Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Mereo BioPharma Group N/A -80.00%-66.94% Does the media prefer SION or MREO? In the previous week, Sionna Therapeutics had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 12 mentions for Sionna Therapeutics and 8 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.88 beat Sionna Therapeutics' score of -0.32 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, SION or MREO? Mereo BioPharma Group has higher revenue and earnings than Sionna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AMereo BioPharma Group$10M27.19-$43.25M-$0.07-24.43 SummaryMereo BioPharma Group beats Sionna Therapeutics on 9 of the 12 factors compared between the two stocks. Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$271.89M$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.10%4.04%P/E Ratio-24.4320.7883.2726.59Price / Sales27.19386.79535.03111.31Price / CashN/A44.2237.4459.26Price / Book5.038.0710.556.58Net Income-$43.25M-$53.98M$3.27B$265.95M7 Day Performance0.59%-0.88%0.40%0.17%1 Month Performance1.18%7.72%7.31%3.90%1 Year Performance-63.54%7.03%46.58%19.67% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group2.0212 of 5 stars$1.71-2.3%$7.40+332.7%-63.5%$271.89M$10M-24.4340SIONSionna Therapeutics1.3884 of 5 stars$24.06-1.4%$38.50+60.0%N/A$1.08BN/A0.0035News CoverageInsider TradeSTOKStoke Therapeutics4.5225 of 5 stars$18.87-3.5%$25.57+35.5%+35.8%$1.07B$36.56M22.20100Positive NewsSYRESpyre Therapeutics3.1668 of 5 stars$16.58-4.6%$53.40+222.1%-42.6%$1.05BN/A-4.8873News CoveragePositive NewsAnalyst DowngradePRAXPraxis Precision Medicines1.6755 of 5 stars$46.94-3.8%$85.88+82.9%-14.3%$1.03B$7.77M-3.82110News CoverageCRMDCorMedix2.6962 of 5 stars$13.73+0.3%$17.33+26.2%+137.7%$1.02B$43.47M18.3130News CoveragePositive NewsCRONCronos Group1.7611 of 5 stars$2.60-0.2%N/A+15.0%$995.90M$117.61M51.90450Analyst UpgradeNUVBNuvation Bio2.312 of 5 stars$2.88-0.7%$7.33+154.6%-7.6%$992.59M$7.87M-4.5760News CoverageVERVVerve Therapeutics2.0032 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110VALNValneva1.9776 of 5 stars$9.43-19.0%$16.00+69.7%+20.2%$990.49M$183.52M-9.62700High Trading VolumeMLYSMineralys Therapeutics3.0661 of 5 stars$14.74-1.0%$32.25+118.8%+24.7%$986.80MN/A-4.1428News CoverageAnalyst Forecast Related Companies and Tools Related Companies SION Competitors STOK Competitors SYRE Competitors PRAX Competitors CRMD Competitors CRON Competitors NUVB Competitors VERV Competitors VALN Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MREO) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MREO Stock Alerts